Advanced Wound Care Vacutex™ incorporates a patented three layer construction of poly-cotton elements that promotes an accelerated capillary action on wound interfaces. Effectively lifting, transporting and retaining exudate and interstitial fluids. Cut Shape Innovate
8
Embed
Cut Shape Innovate - MSA · of poly-cotton elements that promotes an accelerated capillary action on wound interfaces.Effectively lifting, transporting and retaining exudate and interstitial
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Advanced Wound Care
Vacutex™ incorporates a patented three layer constructionof poly-cotton elements that promotes an acceleratedcapillary action on wound interfaces. Effectively lifting,
transporting and retaining exudate and interstitial fluids.
Cut Shape Innovate
Vacutex A5 18/4/06 14:20 Page 1
nivshenko
New Stamp
featuresVacutex’s capillary action removes potentially bacteria-laden exudate, slough and necrotic debrisaway from the wound bed.Vacutex’s capillary action promotes the migration ofessential cells across the wound bed surface.Vacutex is low adherent and can be customised tosuit the wound.Vacutex is highly absorbent.Vacutex promotes rapid granulation.Vacutex bridges the capabiltiy limitations of manyexisting advanced wound care technologies.
bene tsVacutex’s rapid capillary action promotes optimalmoist wound healing.Vacutex is versatile, easy to use and remove.Vacutex is ective in the management of acute andchronic wound indications.Vacutex has the ability to manage low, moderate andhigh levels of exudate.Vacutex is cost ective.Vacutex prevents maceration to the peri-wound area.
Rapid capillaryaction ‘pulls’interstitial away from thewound bed.
1 Locks andredistributes within a central layer,‘wicking’ laterally untilsaturated.
2 Third layer remainsdry until saturationoccurs withincentral layer.
3
indications for useDiabetic woundsPressure ulcersDehisced surgical woundsLeg ulcersBurns
Product Size DressingsCode (cm) per carton
VAC005005 5 x 5 10VAC010010 10 x 10 10VAC010015 10 x 15 10VAC010020 10 x 20 10VAC015020 15 x 20 10VAC020020 20 x 20 10
VCD010100 10 x 100 5 rollsVCD020100 20 x 100 5 rolls
Distributed by:
Vacutex is a trademark of, and manufactured by Protex Healthcare (UK) Ltd
Heel Pressure UlcersPressure ulcers develop as a result of obstructionof blood vessels by unrelieved external pressure.
Moisture and mechanisms such as shear andfriction are often involved in the formation ofpressure ulcers.
These wounds most often manisfest themselves inthe elderly or neurologically compromised patientdue to the reduced ability to reposition.
Grading of pr essur e ulcers
GRADE 1
Non-blanching erythema, discolouration ofthe skin,warmth, oedema, induration orhardness may also be used as indicatorsparticularly on individuals with darker skin.GRADE 2
Partial thickness skin loss or blister,involving epidermis or dermis.GRADE 3
Full thickness skin loss involving damage ornecrosis of subcutaneous tissue which mayextend down to, but not through fascia.GRADE 4
Full thickness skin loss with extensivedestruction, tissue necrosis or damage tomuscle, bone or supporting structure.
Case Study
Heel with signi cantnecrotic eschar visible.Vacutex is capable of‘softening’ the necroticeschar and lifting thedevitalised tissue fromthe wound.
Vacutex’s rapid capillaryaction ‘pulls’anysurrounding slough intothe dressing as theeschar shrinks. In thiscase dressings were cutto a suitable size to coverboth the necrotic andsurrounding area.
Vacutex rapid capillaryaction dressings retainthe exudates and wounddebris within the twolayers of the dressingthus aiding in theprevention of macerationto the surroundinghealthy tissue.
Vacutex rapid capillaryaction dressings havesuccessfully lifted theeschar and clean healthytissue is evident.
Pictures taken at 6 dayintervals*
2
3
4
1
nivshenko
Sticky Note
Unmarked set by nivshenko
Venous Leg Ulcers
When utilised for the management of venous legulcers, Vacutex™ Advanced Wound Careprovides an effective means of:
Removing tenacious slough and necrotic eschar
Protecting surrounding skin from maceration
Promoting rapid granulation
Managing high volumes of exudates
Employing a dressing suitable for use undercompression bandaging
VenousLegUlcers A5 18/4/06 12:21 Page 1
1. Goldman, R. et al. Measured improvement in rate of healing ofvenous ulceration. British Journal of Nursing, 2003 Vol 12, No 3.
2. Deeth, M. and Pain, L.Vacutex; A dressing designed for patients,tailored by nurses. British Journal of Nursing, 2001 Vol 10, No 4.
3. King, R.Venous leg ulceration and the use of Vacutex. Data on le.
Venous Leg UlcersVenous leg ulceration ects an estimated1-2% of the population and 8% of patients will experience re-occurrence of the disease.
A venous leg ulcer is an irregular shapeddeep or partial thickness wound with wellde ned borders, generally surrounded byhyperpigmented indurated skin.
A yellow/white exudate is often visible.Ulcers vary in size and location, but areusually situated in the gaiter region.
Oedema is common around the ankleregion and pain is usually associated withvenous leg ulceration whether in motion,standing or at rest.
The calf m uscle pump
The calf muscle pump initiates the returnof blood from the lower limbs back to theheart.This mechanism consists of calfmuscles, the deep venous system and thesuperficial venous compartment connectedto deep veins through one way valves viasmaller perforator veins.
Malfunctioning of any of these componentsusually leads to venous ulceration.
Case Study
In this case thereis evidence ofnecrosis,infection,and a sloughyregion to thewound area.
Amputation wasthe probableprognosis for thispatient, clinicianelected to applyVactuex rapidcapillary actiondressings.
Granulation isclearly evidentpost two weeksuse of Vactuexrapid capillaryaction dressings.
Granulation andepithelialisation is clearlyevident post 10 days ofdressing with Vactuexrapid capillary actiondressings.
AMPUTATION WAS AVOIDED.
2
3
4
1
Vacutex is a trademark of, and manufactured by Protex Healthcare (UK) Ltd